Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
Other Sizes |
|
Purity: = 98.63%
Targets |
20S proteasome; Pre-mRNA splicing
|
---|---|
ln Vitro |
Isoginkgetin (0-20 μM, 24 h) inhibits cell invasion in a dose-dependent manner[1].
Isoginkgetin (10 μM, 0-24 h) activates autophagy, causes lysosomal swelling, repositioning, and acidification, and causes the accumulation of ubiquitinated protein cargo into perinuclear aggregates[2]. Isoginkgetin (10 μM, 0–6 h) induces ER stress, degrades the unfolded protein response, and causes an accumulation of ERAD substrates[2]. Isoginkgetin interferes with NF-κB signaling and directly inhibits the chymotrypsin, trypsin, and caspase-like activities of the 20S proteasome[2]. In MM cell lines, isoginkgetin (30 μM, 0-24 h) induces apoptosis[2]. |
ln Vivo |
Isoginkgetin (4 mg/kg; i.p.; daily for 14 days) shows anti-inflammatory effects[3].
|
Enzyme Assay |
Akt Kinase Assay [1]
Cells were transfected with hemagglutinin-tagged Akt plasmids and lysed in a buffer solution containing 20 mmol/L Tris-HCl (pH 7.5), 12 mmol/L β-glycerophosphate, 150 mmol/L NaCl, 5 mmol/L EGTA, 10 mmol/L NaF, 1% Triton X-100, 0.5% deoxycholate, 3 mmol/L DTT, 1 mmol/L sodium orthovanadate, 1 mmol/L phenylmethylsulfonyl fluoride, and 1.5% aprotinin. Cell extracts were centrifuged, and 200 μg supernatants were immunoprecipitated with hemagglutinin antibody and protein A-agarose. The beads were washed three times with a solution containing 20 mmol/L Tris-HCl (pH 7.5), 150 mmol/L NaCl, 5 mmol/L EGTA, 2 mmol/L DTT, and 1 mmol/L phenylmethylsulfonyl fluoride. Akt activities were assayed in a reaction mixture consisting of 1 μg histone H2B (in vitro substrate for Akt), 2 μg PKI, 5 μmol/L ATP, and 5 μCi [γ-32P]ATP in a buffer [20 mmol/L HEPES (pH 7.2), 10 mmol/L MgCl2, 10 mmol/L MnCl2, 1 mmol/L DTT, and 0.2 mmol/L EGTA] at 30°C for 20 minutes. Protein kinase assays were terminated by the addition of SDS sample buffer, and the samples were subjected to SDS-PAGE. Phosphorylated proteins were visualized by autoradiography. MMP-9 Activity Assay [1] MMP-9 activity was measured using fluorogenic MMP-9 substrate [N-(2,4-dinitrophenyl)-Pro-Leu-Gly-Leu-Trp-Ala-D-Arg amide; Sigma]. Briefly, conditioned medium was mixed with substrate and incubated at 37°C. Fluorescence was measured by using a fluorometer, according to the instruction from the manufacturer. |
Cell Assay |
Cell Death Assays [1]
Cells were washed once with medium, once with PBS, once with Annexin V–FITC buffer [10 mmol/L HEPES-NaOH (pH 7.4), 140 mmol/L NaCl, 2.5 mmol/L CaCl2], and then incubated for 15 minutes at room temperature with 5 μg/mL Annexin V–FITC. After washing once with Annexin V buffer, the samples were resuspended in the same buffer. Immediately before analysis, 5 μg/mL propidium iodide (Biosource International) were added to distinguish apoptotic cells from necrotic cells, and the cells were analyzed using a flow cytometer. |
Animal Protocol |
Adult male Kunming mice (age 8–10weeks, 30–50 g)[3]
4 mg/kg Daily for 14 days by intraperitoneally (i.p.) prior to LPS (0.83mg/kg) administration. |
References |
|
Molecular Formula |
C32H22O10
|
---|---|
Molecular Weight |
566.51
|
Exact Mass |
566.1213
|
Elemental Analysis |
C, 67.84; H, 3.91; O, 28.24
|
CAS # |
548-19-6
|
Related CAS # |
548-19-6
|
Appearance |
Light yellow to yellow solid powder
|
Source |
Ginkgo biloba
|
LogP |
5.24
|
tPSA |
159.80
|
SMILES |
COC1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C(=C(C=C3O)O)C4=C(C=CC(=C4)C5=CC(=O)C6=C(C=C(C=C6O5)O)O)OC
|
InChi Key |
HUOOMAOYXQFIDQ-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C32H22O10/c1-39-18-6-3-15(4-7-18)26-14-24(38)31-22(36)12-21(35)29(32(31)42-26)19-9-16(5-8-25(19)40-2)27-13-23(37)30-20(34)10-17(33)11-28(30)41-27/h3-14,33-36H,1-2H3
|
Chemical Name |
8-[5-(5,7-dihydroxy-4-oxochromen-2-yl)-2-methoxyphenyl]-5,7-dihydroxy-2-(4-methoxyphenyl)chromen-4-one
|
Synonyms |
IGG; Isoginkgetin
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO: ~100 mg/mL (~176.5 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (3.67 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.08 mg/mL (3.67 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: 1.67 mg/mL (2.95 mM) in 50% PEG300 + 50% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.7652 mL | 8.8260 mL | 17.6519 mL | |
5 mM | 0.3530 mL | 1.7652 mL | 3.5304 mL | |
10 mM | 0.1765 mL | 0.8826 mL | 1.7652 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Isoginkgetin inhibits expression of MMP-9, whereas it increases TIMP-1 expression. Mol Cancer Ther . 2006 Nov;5(11):2666-75. td> |
Isoginkgetin inhibits cell invasion. Mol Cancer Ther . 2006 Nov;5(11):2666-75. td> |
Isoginkgetin sensitizes nutrient-starved cancer cells to apoptotic cell death. Mol Cell Biol . 2019 Apr 30;39(10):e00489-18. td> |
Isoginkgetin induces the perinuclear aggregation of p62/ubiquitin-positive protein cargo. Mol Cell Biol . 2019 Apr 30;39(10):e00489-18. td> |
Isoginkgetin induces ER stress, impairs the unfolded protein response, and results in accumulation of ERAD substrates. Mol Cell Biol . 2019 Apr 30;39(10):e00489-18. td> |
Isoginkgetin induces lysosomal stress and activation of transcription factor TFEB. Mol Cell Biol . 2019 Apr 30;39(10):e00489-18. td> |
Isoginkgetin inhibits the proteolytic activities of purified 20S proteasome and impairs NF-κB signaling. Mol Cell Biol . 2019 Apr 30;39(10):e00489-18. td> |